148 related articles for article (PubMed ID: 11399226)
1. Differences in the human and mouse amino-terminal leader peptides of ornithine transcarbamylase affect mitochondrial import and efficacy of adenoviral vectors.
Ye X; Zimmer KP; Brown R; Pabin C; Batshaw ML; Wilson JM; Robinson MB
Hum Gene Ther; 2001 Jun; 12(9):1035-46. PubMed ID: 11399226
[TBL] [Abstract][Full Text] [Related]
2. Correction of ornithine transcarbamylase deficiency in adult spf(ash) mice and in OTC-deficient human hepatocytes with recombinant adenoviruses bearing the CAG promoter.
Kiwaki K; Kanegae Y; Saito I; Komaki S; Nakamura K; Miyazaki JI; Endo F; Matsuda I
Hum Gene Ther; 1996 May; 7(7):821-30. PubMed ID: 8860834
[TBL] [Abstract][Full Text] [Related]
3. Efficient mitochondrial import of newly synthesized ornithine transcarbamylase (OTC) and correction of secondary metabolic alterations in spf(ash) mice following gene therapy of OTC deficiency.
Zimmer KP; Bendiks M; Mori M; Kominami E; Robinson MB; Ye X; Wilson JM
Mol Med; 1999 Apr; 5(4):244-53. PubMed ID: 10448647
[TBL] [Abstract][Full Text] [Related]
4. Efficient adenoviral-mediated ornithine transcarbamylase expression in deficient mouse and human hepatocytes.
Morsy MA; Alford EL; Bett A; Graham FL; Caskey CT
J Clin Invest; 1993 Sep; 92(3):1580-6. PubMed ID: 8376608
[TBL] [Abstract][Full Text] [Related]
5. In vivo assessment of mutations in OTC for dominant-negative effects following rAAV2/8-mediated gene delivery to the mouse liver.
Ginn SL; Cunningham SC; Zheng M; Spinoulas A; Carpenter KH; Alexander IE
Gene Ther; 2009 Jun; 16(6):820-3. PubMed ID: 19357713
[TBL] [Abstract][Full Text] [Related]
6. Long-term correction of ammonia metabolism and prolonged survival in ornithine transcarbamylase-deficient mice following liver-directed treatment with adeno-associated viral vectors.
Moscioni D; Morizono H; McCarter RJ; Stern A; Cabrera-Luque J; Hoang A; Sanmiguel J; Wu D; Bell P; Gao GP; Raper SE; Wilson JM; Batshaw ML
Mol Ther; 2006 Jul; 14(1):25-33. PubMed ID: 16677864
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial import and processing of mutant human ornithine transcarbamylase precursors in cultured cells.
Isaya G; Fenton WA; Hendrick JP; Furtak K; Kalousek F; Rosenberg LE
Mol Cell Biol; 1988 Dec; 8(12):5150-8. PubMed ID: 3244350
[TBL] [Abstract][Full Text] [Related]
8. Long-term correction of ornithine transcarbamylase deficiency by WPRE-mediated overexpression using a helper-dependent adenovirus.
Mian A; McCormack WM; Mane V; Kleppe S; Ng P; Finegold M; O'Brien WE; Rodgers JR; Beaudet AL; Lee B
Mol Ther; 2004 Sep; 10(3):492-9. PubMed ID: 15336649
[TBL] [Abstract][Full Text] [Related]
9. Import of rat ornithine transcarbamylase precursor into mitochondria: two-step processing of the leader peptide.
Sztul ES; Hendrick JP; Kraus JP; Wall D; Kalousek F; Rosenberg LE
J Cell Biol; 1987 Dec; 105(6 Pt 1):2631-9. PubMed ID: 3693395
[TBL] [Abstract][Full Text] [Related]
10. Gene therapy for ornithine transcarbamylase deficiency.
Kiwaki K; Matsuda I
Acta Paediatr Jpn; 1996 Apr; 38(2):189-92. PubMed ID: 8677801
[TBL] [Abstract][Full Text] [Related]
11. The ornithine transcarbamylase leader peptide directs mitochondrial import through both its midportion structure and net positive charge.
Horwich AL; Kalousek F; Fenton WA; Furtak K; Pollock RA; Rosenberg LE
J Cell Biol; 1987 Aug; 105(2):669-77. PubMed ID: 3624306
[TBL] [Abstract][Full Text] [Related]
12. Transient depletion of CD4 lymphocyte improves efficacy of repeated administration of recombinant adenovirus in the ornithine transcarbamylase deficient sparse fur mouse.
Ye X; Robinson MB; Pabin C; Batshaw ML; Wilson JM
Gene Ther; 2000 Oct; 7(20):1761-7. PubMed ID: 11083498
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic correction of ornithine transcarbamylase deficiency using low dose helper-dependent adenoviral vectors.
Brunetti-Pierri N; Clarke C; Mane V; Palmer DJ; Lanpher B; Sun Q; O'Brien W; Lee B
J Gene Med; 2008 Aug; 10(8):890-6. PubMed ID: 18563850
[TBL] [Abstract][Full Text] [Related]
14. Expression of amplified DNA sequences for ornithine transcarbamylase in HeLa cells: arginine residues may be required for mitochondrial import of enzyme precursor.
Horwich AL; Fenton WA; Firgaira FA; Fox JE; Kolansky D; Mellman IS; Rosenberg LE
J Cell Biol; 1985 May; 100(5):1515-21. PubMed ID: 3988798
[TBL] [Abstract][Full Text] [Related]
15. High-level expression of a mitochondrial enzyme, ornithine transcarbamylase from rat liver, in a baculovirus expression system.
Lithgow T; Ristevski S; Höj P; Hoogenraad N
DNA Cell Biol; 1991; 10(6):443-9. PubMed ID: 2069719
[TBL] [Abstract][Full Text] [Related]
16. Prolonged metabolic correction in adult ornithine transcarbamylase-deficient mice with adenoviral vectors.
Ye X; Robinson MB; Batshaw ML; Furth EE; Smith I; Wilson JM
J Biol Chem; 1996 Feb; 271(7):3639-46. PubMed ID: 8631974
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector.
Stratford-Perricaudet LD; Levrero M; Chasse JF; Perricaudet M; Briand P
Hum Gene Ther; 1990; 1(3):241-56. PubMed ID: 2081192
[TBL] [Abstract][Full Text] [Related]
18. Patient selection may affect gene therapy success. Dominant negative effects observed for ornithine transcarbamylase in mouse and human hepatocytes.
Morsy MA; Zhao JZ; Ngo TT; Warman AW; O'Brien WE; Graham FL; Caskey CT
J Clin Invest; 1996 Feb; 97(3):826-32. PubMed ID: 8609240
[TBL] [Abstract][Full Text] [Related]
19. Targeting of pre-ornithine transcarbamylase to mitochondria: definition of critical regions and residues in the leader peptide.
Horwich AL; Kalousek F; Fenton WA; Pollock RA; Rosenberg LE
Cell; 1986 Feb; 44(3):451-9. PubMed ID: 3943133
[TBL] [Abstract][Full Text] [Related]
20. Developing adenoviral-mediated in vivo gene therapy for ornithine transcarbamylase deficiency.
Raper SE; Wilson JM; Yudkoff M; Robinson MB; Ye X; Batshaw ML
J Inherit Metab Dis; 1998; 21 Suppl 1():119-37. PubMed ID: 9686350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
